Close

TRIM2

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The protein encoded by this gene is a member of the tripartite motif (TRIM) family. The TRIM motif includes three zinc-binding domains, a RING, a B-box type 1 and a B-box type 2, and a coiled-coil region. The protein localizes to cytoplasmic filaments. It plays a neuroprotective role and functions as an E3-ubiquitin ligase in proteasome-mediated degradation of target proteins. Mutations in this gene can cause early-onset axonal neuropathy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Nov 2014]
  • CAR Vector Products

  • DMAb

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
CAR-LY924 Anti-TRIM2 (1D12) h(41BB-CD3ζ) CAR, pCDCAR1 Human 1D12 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-LY925 Anti-TRIM2 (1D2) h(41BB-CD3ζ) CAR, pCDCAR1 Human 1D2 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-LY926 Anti-TRIM2 (2B10) h(41BB-CD3ζ) CAR, pCDCAR1 Human 2B10 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-LY927 Anti-TRIM2 (2B2) h(41BB-CD3ζ) CAR, pCDCAR1 Human 2B2 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-LY928 Anti-TRIM2 (3B5) h(41BB-CD3ζ) CAR, pCDCAR1 Human 3B5 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-LY929 Anti-TRIM2 (4D6) h(41BB-CD3ζ) CAR, pCDCAR1 Human 4D6 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-LY930 Anti-TRIM2 (4E5) h(41BB-CD3ζ) CAR, pCDCAR1 Human 4E5 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-LY931 Anti-TRIM2 (5G7) h(41BB-CD3ζ) CAR, pCDCAR1 Human 5G7 Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-LY2564 Anti-TRIM2(1D12) h(CD28-CD3ζ) CAR, pCDCAR1 Human 1D12 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-LY2565 Anti-TRIM2(1D2) h(CD28-CD3ζ) CAR, pCDCAR1 Human 1D2 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-LY2566 Anti-TRIM2(2B10) h(CD28-CD3ζ) CAR, pCDCAR1 Human 2B10 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-LY2567 Anti-TRIM2(2B2) h(CD28-CD3ζ) CAR, pCDCAR1 Human 2B2 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-LY2568 Anti-TRIM2(3B5) h(CD28-CD3ζ) CAR, pCDCAR1 Human 3B5 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-LY2569 Anti-TRIM2(4D6) h(CD28-CD3ζ) CAR, pCDCAR1 Human 4D6 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-LY2570 Anti-TRIM2(4E5) h(CD28-CD3ζ) CAR, pCDCAR1 Human 4E5 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-LY2571 Anti-TRIM2(5G7) h(CD28-CD3ζ) CAR, pCDCAR1 Human 5G7 Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.